受体相互作用蛋白激酶1 (RIPK1):在缺血性中风中具有潜在的治疗标
Zijun Liu1, Fenglian Xu1, Ziyu Wang1
1Department of Basic Medicine, Department of Physiology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Tongjiaxiang 24, Nanjing, 210009, People's Republic of China.
Molecular neurobiology
|January 14, 2026
概括
受体相互作用蛋白激酶1 (RIPK1) 通过调节细胞死亡和炎症,在缺血性中风中至关重要. 了解 RIPK1 的理解
科学领域:
- 分子生物学分子生物学
- 神经科学是一个神经科学.
- 病理学 病理学 病理学
背景情况:
- 受体相互作用蛋白激酶1 (RIPK1) 是细胞死亡和炎症的关键调节者.
- 在缺血性中风中RIPK1的作用尚不完全理解,尽管已知它与其他疾病有关.
- 翻译后的修改显著影响了RIPK1的活动和功能.
研究的目的:
- 审查RIPK1.1的分子结构,功能和调节网络.
- 阐明RIPK1在缺血性中风病理学的机制.
- 讨论RIPK1抑制剂在缺血性中风中的潜在治疗应用.
主要方法:
- 文献综述总结了关于RIPK1.1的当前研究.
- 对RIPK1参与细胞死亡途径 (细胞亡,亡) 的分析.
- 检查RIPK1在神经炎症和NF-κB激活中的作用.
- 审查RIPK1对血脑屏障完整性的影响.
- 对RIPK1抑制剂开发和临床试验的概述.
主要成果:
- 在缺血性中风中,RIPK1调节了亡和亡细胞死亡级联.
- RIPK1有助于神经炎症和NF-κB通路的激活,影响中风的结果.
- RIPK1在维持血脑屏障完整性方面发挥着作用.
- RIPK1显示出作为缺血性脑损伤的诊断标记物的潜力.
结论:
- RIPK1是缺血性中风的关键调解者,影响细胞死亡,神经炎症和BBB完整性.
- 准RIPK1为缺血性中风提供了一个有前途的治疗策略.
- 对RIPK1调节和抑制剂开发的进一步研究是必要的.
相关概念视频
01:31Regulation of the Unfolded Protein Response
2.9K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.9K
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.9K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.9K
01:22PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
01:20The JAK-STAT Signaling Pathway
12.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
12.0K
01:26Receptor Tyrosine Kinases
18.0K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
18.0K
01:22Amplifying Signals via Enzymatic Cascade
17.3K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
17.3K